Immune Checkpoint Inhibitor-Related Pneumonitis

被引：41
|
作者：
Gomatou, Georgia [1 ,2 ]
Tzilas, Vasilios [1 ]
Kotteas, Elias [2 ]
Syrigos, Konstantinos [2 ]
Bouros, Demosthenes [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sotiria Hosp Dis Chest, Dept Resp Med 1, Interstitial Lung Dis Unit, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sotiria Hosp Dis Chest, Dept Med 3, Oncol Unit, Athens, Greece
来源：
RESPIRATION | 2021年 / 99卷 / 11期
关键词：
Immune checkpoint inhibitor; Immunotherapy; Pneumonitis; Interstitial lung disease; CELL LUNG-CANCER; ADVERSE EVENTS; COMBINATION IMMUNOTHERAPY; NIVOLUMAB; TOXICITY; RISK; PEMBROLIZUMAB; ASSOCIATION; DOCETAXEL; DIAGNOSIS;
D O I：
10.1159/000509941
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Immune checkpoint inhibitors are novel agents that have been proved efficacious in a variety of cancer types, but they are associated with a unique set of organ-specific, immune-related adverse events. Among them, immune-related pneumonitis requires special attention because it is difficult to diagnose and potentially lethal. Accumulating real-world epidemiological data suggest that immune-related pneumonitis is more frequent than previously reported. Its diagnosis requires exclusion of other causes and assessment of radiographic features on high-resolution CT of the chest. Management of immune-related pneumonitis is based on the use of immunosuppressants. Future research should be focused on finding predictive biomarkers for immune-related pneumonitis as well as optimizing its management.
引用
收藏
页码：932 / 942
页数：11
相关论文
共 50 条
  • [1] The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis
    Asada, Mizuho
    Mikami, Takahisa
    Niimura, Takahiro
    Zamami, Yoshito
    Uesawa, Yoshihiro
    Chuma, Masayuki
    Ishizawa, Keisuke
    ONCOLOGY, 2021, 99 (04) : 256 - 259
  • [2] Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
    Poulose, Vijo
    CHEST, 2022, 161 (03) : E196 - E197
  • [3] Expansion of inflammatory macrophages in immune checkpoint inhibitor-related pneumonitis
    Cui, Xiaoran
    Hu, Yi
    Liu, Tianyi
    Zhi, Renyong
    Wu, Liangliang
    Yu, Yanju
    Li, Tao
    CANCER SCIENCE, 2025, 116 : 1154 - 1154
  • [4] Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
    Larsen, Brandon T.
    Chae, June M.
    Dixit, Anuj S.
    Hartman, Thomas E.
    Peikert, Tobias
    Roden, Anja C.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (10) : 1331 - 1340
  • [5] Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
    Lin, Mei-Xi
    Zang, Dan
    Liu, Chen-Guang
    Han, Xu
    Chen, Jun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [6] Spontaneous Pneumomediastinum in a Fatal Case of Immune Checkpoint Inhibitor-Related Pneumonitis
    Al-Nusair, M.
    Karbowitz, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [7] Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Response
    Atchley, William T.
    Rock, Little
    Alvarez, Carolina
    Saxena-Beem, Shruti
    Schwartz, Todd A.
    Ishizawar, Rumey C.
    Patel, Kunal P.
    Rivera, M. Patricia
    CHEST, 2022, 161 (03) : E197 - E197
  • [8] A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis
    Lee, Ho Yun
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1440 - 1442
  • [9] Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review
    Wang, Yuan-Di
    Yuan, Shengfang
    Wen, Cuiling
    Ji, Zexuan
    Xiang, Baoli
    Wang, Bu
    Zhang, Zhihua
    IMMUNOTHERAPY, 2023, 15 (14) : 1117 - 1123
  • [10] The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence
    Guo, Cuiyan
    Zhang, Qi
    Zhou, Peining
    Cheng, Yuan
    Nie, Ligong
    Wang, Guangfa
    SCIENTIFIC REPORTS, 2024, 14 (01):
12345